Differential Effects of Ethanol on Spectral Binding and Inhibition of Cytochrome P450 3A4 with Eight Protease Inhibitors Antiretroviral Drugs

Alcoholism: Clinical and Experimental Research

Volumn 35, Issue 12, 2011, Pages 2121-2127

  Kumar, Santosh ^a   Kumar, Anil ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Alcohol; CYP3A4; Inhibition; Protease Inhibitors; Spectral Binding

Indexed keywords

7 BENZYLOXY 4 TRIFLUOROMETHYLCOUMARIN; ALCOHOL; AMPRENAVIR; ATAZANAVIR; COUMARIN; CYTOCHROME P450 3A4; DARUNAVIR; INDINAVIR; LOPINAVIR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RITONAVIR; SAQUINAVIR; TIPRANAVIR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DRUG STRUCTURE; ENZYME BINDING; ENZYME INHIBITION; IC 50; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

ANTI-RETROVIRAL AGENTS; CYTOCHROME P-450 CYP3A; ETHANOL; HUMANS; PROTEASE INHIBITORS; PROTEIN BINDING;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 81855183205     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2011.01575.x     Document Type: Article

References (38)

1. Acosta EP (2002) Pharmacokinetic enhancement of protease inhibitors. J Acquir Immune Defic Syndr 29:S11-S18.
2. Anzenbacher P, Anzenbacherová E (2002) Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 58:737-747.
3. Arvieux C, Tribut O (2005) Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile. Drugs 65:633-659.
4. Croom KF, Dhillon S, Keam SJ (2009) Atazanavir: a review of its use in the management of HIV-1 infection. Drugs 69:1107-1140.
5. Croxtall JD, Perry CM (2010) Lopinavir/ritonavir: a review of its use in the management of HIV-1 infection. Drugs 70:1885-1915.
6. Davydov DR, Halpert JR (2008) Allosteric P450 mechanisms: multiple binding sites, multiple conformers or both? Expert Opin Drug Metab Toxicol 4:1523-1535.
7. De Clercq E (2009a) The history of antiretrovirals: key discoveries over the past 25years. Rev Med Virol 19:287-299.
8. De Clercq E (2009b) Anti-HIV drugs: 25 compounds approved within 25years after the discovery of HIV. Int J Antimicrob Agents 33:307-320.
9. Domanski TL, He YA, Khan KK, Roussel F, Wang Q, Halpert JR (2001) Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. Biochemistry 40:10150-10160.
10. Dwyer DS, Bradley RJ (2000) Chemical properties of alcohols and their protein binding sites. Cell Mol Life Sci 57:265-275.
11. Eagling VA, Back DJ, Barry MG (1997) Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 44:190-194.
12. Flexner CW, Cargill VA, Sinclair J, Kresina TF, Cheever L (2002) Alcohol use can result in enhanced drug metabolism in HIV pharmacotherapy. AIDS Patient Care STDS 15:57-58.
13. Fraser AG (1997) Pharmacokinetic interactions between alcohol and other drugs. Clin Pharmacokinet 33:79-90.
14. Gavegnano C, Schinazi RF (2009) Antiretroviral therapy in macrophages: implication for HIV eradication. Antivir Chem Chemother 20:63-78.
15. Granfors MT, Wang JS, Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT (2006) Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Clin Pharmacol Toxicol 98:79-85.
16. Harlow GR, Halpert JR (1998) Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displayes hyperbolic steroids hydroxylation kinetics. Proc Natl Acad Sci USA 95:6636-6641.
17. Hosea NA, Miller GP, Guengerich FP (2000) Elucidation of distinct ligand binding sites for cytochrome P450 3A4. Biochemistry 39:5929-5939.
18. Jiménez-Nácher I, García B, Barreiro P, Rodriguez-Novoa S, Morello J, González-Lahoz J, de Mendoza C, Soriano V (2008) Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. J Antimicrob Chemother 62:816-822.
19. Jin M, Arya P, Patel K, Singh B, Silverstein P, Bhat H, Kumar A, Kumar S (2011) Effect of alcohol on drug efflux protein and drug metabolic enzymes in U937 macrophages. Alcohol Clin Exp Res 35:132-139.
20. Kalichman SC, Amaral CM, White D, Swetsze Pope CH, Kalichman MO, Cherry C, Eaton L (2009) Prevalence and clinical implications of interactive toxicity beliefs regarding mixing alcohol and antiretroviral therapies among people living with HIV/AIDS. AIDS Patient Care STDS 23:449-454.
21. Kresina TF, Flexner C, Sinclair WJ, Correia MA, Stapleton JT, Adeniyi-Jones S (2002) Alcohol use and HIV pharmacotherapy. AIDS Res Hum Retroviruses 18:757-770.
22. 5 in modulating peroxide-supported CYP3A4 activity: evidence for a conformational transition and cytochrome P450 heterogeneity. Drug Metab Dispos 33:1131-1136.
23. Kumar S, Earla R, Jin M, Mitra AK, Kumar A (2010) Effect of ethanol on spectral binding, inhibition, and activity of CYP3A4 with an antiretroviral drug nelfinavir. Biochem Biophys Res Commun 402:163-167.
24. Kumar S, Liu H, Halpert JR (2006) Engineering of cytochrome P450 3A4 for enhanced peroxide-mediated substrate oxidation using directed evolution and site-directed mutagenesis. Drug Metab Dispos 34:1958-1965.
25. McKeage K, Perry CM, Keam SJ (2009) Darunavir: a review of its use in the management of HIV infection in adults. Drugs 69:477-503.
26. Miguez MJ, Shor-Posner G, Morales G, Rodriguez A, Burbano X (2003) HIV treatment in drug abusers: impact of alcohol use. Addict Biol 8:33-37.
27. Muralidhara BK, Negi S, Chin CC, Braun W, Halpert JR (2006) Conformational flexibility of mammalian cytochrome P450 2B4 in binding imidazole inhibitors with different ring chemistry and side chains. Solution thermodynamics and molecular modeling. J Biol Chem 281:8051-8061.
28. Pal D, Mitra AK (2006) MDR- and CYP3A4-mediated drug-drug interactions. J Neuroimmune Pharmacol 1:323-339.
29. Renaud JP, Davydov DR, Heirwegh KP, Mansuy D, Hui Bon Hoa GH (1996) Thermodynamic studies of substrate binding and spin transitions in human cytochrome P-450 3A4 expressed in yeast microsomes. Biochem J 319:675-681.
30. Rittweger M, Arastéh K (2007) Clinical pharmacokinetics of darunavir. Clin Pharmacokinet 46:739-756.
31. Roberts AG, Campbell AP, Atkins WM (2005) The thermodynamic landscape of testosterone binding to cytochrome P450 3A4: ligand binding and spin state equilibria. Biochemistry 44:1353-1366.
32. Roberts NA, Craig JC, Duncan IB (1992) HIV protease inhibitors. Biochem Soc Trans 20:513-516.
33. Shibata N, Kageyama M, Kimura K, Tadano J, Hukushima H, Namiki H, Yoshikawa Y, Takada K (2004) Evaluation of factors to decrease plasma concentration of an HIV protease inhibitor, saquinavir in ethanol-treated rats. Biol Pharm Bull 27:203-209.
34. Talakad JC, Kumar S, Halpert JR (2009) Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs. Drug Metab Dispos 37:644-650.
35. Walubo A (2007) The role of cytochrome P450 in antiretroviral drug interactions. Expert Opin Drug Toxicol 3:583-598.
36. Weathermon R, Crabb DW (1999) Alcohol and medication interactions. Alcohol Res Health 23:40-54.
37. Xu L, Desai MC (2009) Pharmacokinetic enhancers for HIV drugs. Curr Opin Investig Drugs 10:775-786.
38. Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL (2005) Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44:279-304.